Anthracycline-induced Cardiotoxicity: Mechanisms, Monitoring, and Prevention

Overview

Journal Front Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2024 Jan 4

PMID 38173817

Authors

Yun Qiu

Piao Jiang

Yingmei Huang

Affiliations

Soon will be listed here.

Abstract

Anthracyclines are the most fundamental and important treatment of several cancers especially for lymphoma and breast cancer. However, their use is limited by a dose-dependent cardiotoxicity which may emerge early at the initiation of anthracycline administration or several years after termination of the therapy. A full comprehending of the mechanisms of anthracycline-induced cardiotoxicity, which has not been achieved and is currently under the efforts, is critical to the advance of developing effective methods to protect against the cardiotoxicity, as well as to early detect and treat it. Therefore, we review the recent progress of the mechanism underlying anthracycline-induced cardiotoxicity, as well as approaches to monitor and prevent this issue.

Citing Articles

Validation of novel predictors for early detection of cancer therapeutics-related cardiac dysfunction.

Mahmoud M, Morsy M, Abdel Ghany M, Idriss N, Helmy H, Kishk Y Future Cardiol. 2025; 21(4):229-235.

PMID: 39957243 PMC: 11901396. DOI: 10.1080/14796678.2025.2466379.

Euodiae Fructus: a review of botany, application, processing, phytochemistry, quality control, pharmacology, and toxicology.

Hao Y, Qi J, Huang X, Liu C, Liu Y Front Pharmacol. 2025; 16:1509032.

PMID: 39944619 PMC: 11813794. DOI: 10.3389/fphar.2025.1509032.

Anthracycline-induced cardiomyopathy: risk prediction, prevention and treatment.

Fabiani I, Chianca M, Cipolla C, Cardinale D Nat Rev Cardiol. 2025; .

PMID: 39875555 DOI: 10.1038/s41569-025-01126-1.

Potential Protective Effect of Orlistat: A Formulation of Nanocrystals Targeting Inflammation, Oxidative Stress, and Apoptosis in an Experimental Model of Doxorubicin-Induced Cardiotoxicity.

Alsunbul M, El-Masry T, El Zahaby E, Gaballa M, El-Nagar M Pharmaceutics. 2024; 16(11).

PMID: 39598480 PMC: 11597902. DOI: 10.3390/pharmaceutics16111356.

Anthracycline Cardiotoxicity in Adult Cancer Patients: State-of-the-Art Review.

Camilli M, Cipolla C, Dent S, Minotti G, Cardinale D JACC CardioOncol. 2024; 6(5):655-677.

PMID: 39479333 PMC: 11520218. DOI: 10.1016/j.jaccao.2024.07.016.

References

Porta-Sanchez A, Gilbert C, Spears D, Amir E, Chan J, Nanthakumar K . Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review. J Am Heart Assoc. 2017; 6(12). PMC: 5779062. DOI: 10.1161/JAHA.117.007724. View

Wu R, Wang H, Yu H, Cui X, Xu M, Xu X . Doxorubicin toxicity changes myocardial energy metabolism in rats. Chem Biol Interact. 2016; 244:149-58. DOI: 10.1016/j.cbi.2015.12.010. View

Caspar T, Fichot M, Ohana M, Ghannudi S, Morel O, Ohlmann P . Late Detection of Left Ventricular Dysfunction Using Two-Dimensional and Three-Dimensional Speckle-Tracking Echocardiography in Patients with History of Nonsevere Acute Myocarditis. J Am Soc Echocardiogr. 2017; 30(8):756-762. DOI: 10.1016/j.echo.2017.04.002. View

Armenian S, Hudson M, Mulder R, Chen M, Constine L, Dwyer M . Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol. 2015; 16(3):e123-36. PMC: 4485458. DOI: 10.1016/S1470-2045(14)70409-7. View

Pudil R, Mueller C, Celutkiene J, Henriksen P, Lenihan D, Dent S . Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Eur J Heart Fail. 2020; 22(11):1966-1983. DOI: 10.1002/ejhf.2017. View

Acar Z, Kale A, Turgut M, Demircan S, Durna K, Demir S . Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2011; 58(9):988-9. DOI: 10.1016/j.jacc.2011.05.025. View

Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni C, Veglia F . Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015; 131(22):1981-8. DOI: 10.1161/CIRCULATIONAHA.114.013777. View

Sun A, Cheng Y, Zhang Y, Zhang Q, Wang S, Tian S . Aldehyde dehydrogenase 2 ameliorates doxorubicin-induced myocardial dysfunction through detoxification of 4-HNE and suppression of autophagy. J Mol Cell Cardiol. 2014; 71:92-104. DOI: 10.1016/j.yjmcc.2014.01.002. View

Ferreira L, Cunha-Oliveira T, Veloso C, Costa C, Wallace K, Oliveira P . Single nanomolar doxorubicin exposure triggers compensatory mitochondrial responses in H9c2 cardiomyoblasts. Food Chem Toxicol. 2018; 124:450-461. DOI: 10.1016/j.fct.2018.12.017. View

10.

Russo M, Della Sala A, Tocchetti C, Porporato P, Ghigo A . Metabolic Aspects of Anthracycline Cardiotoxicity. Curr Treat Options Oncol. 2021; 22(2):18. PMC: 7864817. DOI: 10.1007/s11864-020-00812-1. View

11.

Janbabai G, Nabati M, Faghihinia M, Azizi S, Borhani S, Yazdani J . Effect of Enalapril on Preventing Anthracycline-Induced Cardiomyopathy. Cardiovasc Toxicol. 2016; 17(2):130-139. DOI: 10.1007/s12012-016-9365-z. View

12.

Huelsenbeck J, Henninger C, Schad A, Lackner K, Kaina B, Fritz G . Inhibition of Rac1 signaling by lovastatin protects against anthracycline-induced cardiac toxicity. Cell Death Dis. 2011; 2:e190. PMC: 3181415. DOI: 10.1038/cddis.2011.65. View

13.

Raj S, Franco V, Lipshultz S . Anthracycline-induced cardiotoxicity: a review of pathophysiology, diagnosis, and treatment. Curr Treat Options Cardiovasc Med. 2014; 16(6):315. DOI: 10.1007/s11936-014-0315-4. View

14.

Keizer H, Pinedo H, Schuurhuis G, Joenje H . Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol Ther. 1990; 47(2):219-31. DOI: 10.1016/0163-7258(90)90088-j. View

15.

An J, Li P, Li J, Dietz R, Donath S . ARC is a critical cardiomyocyte survival switch in doxorubicin cardiotoxicity. J Mol Med (Berl). 2009; 87(4):401-10. DOI: 10.1007/s00109-008-0434-z. View

16.

Herrmann J . Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol. 2020; 17(8):474-502. PMC: 8782611. DOI: 10.1038/s41569-020-0348-1. View

17.

Tan C, Tasaka H, Yu K, Murphy M, KARNOFSKY D . Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer. 1967; 20(3):333-53. DOI: 10.1002/1097-0142(1967)20:3<333::aid-cncr2820200302>3.0.co;2-k. View

18.

Leger K, Slone T, Lemler M, Leonard D, Cochran C, Bowman W . Subclinical cardiotoxicity in childhood cancer survivors exposed to very low dose anthracycline therapy. Pediatr Blood Cancer. 2014; 62(1):123-7. DOI: 10.1002/pbc.25206. View

19.

Bosch X, Sitges M, Rovira M, Ortiz-Perez J, Esteve J . Reply: Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies. J Am Coll Cardiol. 2013; 62(25):2452. DOI: 10.1016/j.jacc.2013.08.712. View

20.

Bountioukos M, Doorduijn J, Roelandt J, Vourvouri E, Bax J, Schinkel A . Repetitive dobutamine stress echocardiography for the prediction of anthracycline cardiotoxicity. Eur J Echocardiogr. 2003; 4(4):300-5. DOI: 10.1016/s1525-2167(03)00017-9. View